Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:SBOT

Stellar Biotechnologies (SBOT) Stock Price, News & Analysis

Stellar Biotechnologies logo

About Stellar Biotechnologies Stock (NASDAQ:SBOT)

Key Stats

Today's Range
$10.02
$10.58
50-Day Range
$4.44
$298,098.00
52-Week Range
$0.75
$3.25
Volume
3.42 million shs
Average Volume
2.95 million shs
Market Capitalization
$53.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein in Europe, North America, and Asia. The company offers KLH, an immune-stimulating protein used in the production of various immunotherapies; and as a carrier molecule or finished injectable product in the immunodiagnostic market. It provides its KLH protein under the Stellar KLH brand. The company's products include Stellar KLH protein in various grades, formulations, custom configurations, and fill finishes for drug development and research applications, as well as KLH-based in vitro diagnostic kits for research and preclinical use. Its customers and partners comprise biotechnology and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. Stellar Biotechnologies, Inc. is based in Port Hueneme, California.

Receive SBOT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stellar Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

SBOT Stock News Headlines

Market "Famine" Coming
Market Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicted the 2020 crash a month before it happened...
Stellar Bancorp, Inc. Declares Quarterly Dividend
See More Headlines

SBOT Stock Analysis - Frequently Asked Questions

Stellar Biotechnologies Inc (NASDAQ:SBOT) released its quarterly earnings data on Wednesday, May, 8th. The biotechnology company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by $0.05. The biotechnology company had revenue of $0.12 million for the quarter, compared to analysts' expectations of $0.11 million. Stellar Biotechnologies had a negative net margin of 1,782.64% and a negative trailing twelve-month return on equity of 51.12%.

Stellar Biotechnologies's stock reverse split on the morning of Monday, May 7th 2018. The 1-7 reverse split was announced on Friday, April 27th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 4th 2018. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Stellar Biotechnologies investors own include NightHawk Biosciences (NHWK), NexGen Energy (NXE), XOMA (XOMA), Anavex Life Sciences (AVXL), EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK) and Rigel Pharmaceuticals (RIGL).

Company Calendar

Last Earnings
5/08/2019
Today
11/02/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SBOT
Fax
N/A
Employees
25
Year Founded
N/A

Profitability

Net Income
$-5,030,000.00
Net Margins
-1,782.64%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$210,000.00
Book Value
$2.12 per share

Miscellaneous

Free Float
N/A
Market Cap
$53.51 million
Optionable
Not Optionable
Beta
N/A
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:SBOT) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners